Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/31/2007

SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 6, 2007 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview of the company and its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Develop
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... Declaring that Primary care medicine is in a pre...nt of the American College of Physicians (ACP), to...ers and consumers to issue a call for comprehensiv...nternists and other primary care physicians. , ...care medicine in the U.S., Dr. Dale and other pane...
(Date:5/16/2008)... Fundraiser Seeks to Raise $38 Million for Life-th...ire-USNewswire/ -- Walkers in nearly,every state w...- May 17 and,18 -- by participating in GREAT STRID...c Fibrosis Foundation announced today., May is Na...rosis is a,life-threatening genetic disease that c...
(Date:5/16/2008)...untry needs is more unemployed politicians - and e...stCall/ -- Although nearly all,voters place health...list,a looming federal budgetary crunch means non...current presidential candidates is likely to becom...ty Leader Bill Frist., Jousting with Princeton Un...
(Date:5/16/2008)..., May 16 /PRNewswire-USNewswire/ -- As tropical st...rrawaddy delta, survivors of,Cyclone Nargis are vu...ny,survivors still need assistance, as exposure to... increasingly dire situation., "The people living...cover from this disaster and get back on their fee...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
... are particularly sensitive to cancer-causing poll...udied pregnant women and their newborn babies // ....ants is more harmful to fetuses than their mothers... out most of the pollutants. These researchers won...
...hows that estrogen therapy does not decrease, but ...sal women, say researchers //.Previous studies hav...strogen use and lower risk of dementia. A placebo-... plus progestin in women aged 65 to 79 years looke...
...hows dogs may be able to anticipate seizures in ch...vior from the dogs in this study was // licking, ...ivity, whimpering, and “protective" behavior witho...zure-sensitive dogs reported that licking may abor...
...often leaves cancer patients feeling sick and with...ith advanced cancer, the treatment // and all they...cancer. Now, doctors are taking a new, more target...Perfusion therapy is the most aggressive way avail...
Other Medicine News:
(Date:5/16/2008)...resentations at ASCO Annual Meeting Will Further D... in Front-line Multiple Myeloma -, CAMBRIDGE, Mas...als,The Takeda Oncology Company, today announced ...heduled to be featured at the 2008 American Societ...icago, Illinois, May 30 -,June 3, 2008. The data w...
(Date:5/16/2008)...akers include industry and customer thought leader... Inc., the recognized,leader and trusted resource ...sted a constellation of prestigious academic medic...tners at its annual user group meeting in San,Fran... to internally and,collaboratively manage thousand...
(Date:5/16/2008)... Include:, -- Results demonstrating that TYKERB a...eaningful extension of progression-free survival (...ck both the inside and,outside of the HER2 recepto...ta demonstrating activity of TYKERB alone despite ...f trastuzumab and chemotherapy, LONDON and PHILAD...
(Date:5/16/2008)....J., May 16 /- Veridex, LLC announced... Corporation of America Holdings,(LabCorp), has co...r,prostate cancer. The new assay uses the biologic...ncer, detecting the methylation of the gene,GST-Pi... primarily in,cancer. Veridex is developing the me...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 1Hormone Replacement May Cut Risk for Age Linked Eye Disease 16759 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 1Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 2Study details cost effectiveness of rheumatoid arthritis treatments for Medicare recipients 16754 3Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 1Consumer Watchdog Gives HMO Regulator 10 Days to Order Reinstatement of Patients Whose Policies Have Been Illegally Cancelled 16750 2Clues to ancestral origin of placenta emerge in Stanford study 2886 1Clues to ancestral origin of placenta emerge in Stanford study 2886 2Clues to ancestral origin of placenta emerge in Stanford study 2886 3
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: